• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Peginesatide is noninferior to epoetin for anemia in hemodialysis patients [EMERALD Trials]

bys25qthea
November 24, 2015
in Chronic Disease, Nephrology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Hemodialysis patients who received peginesatide had similar hemoglobin levels and similar rates of adverse events as patients who received traditional epoetin treatments.

Published today in NEJM, The EMERALD 1 and 2 trials evaluated the safety and efficacy of peginesatide for treatment of anemia in hemodialysis patients.

The study effectively demonstrated that peginesatide administered once a month was non-inferior to traditional erythropoiesis stimulating agents (ESAs) in maintaining hemoglobin at target levels.  This was found to be true for chronic kidney disease patients not on dialysis as well, albeit with a higher adverse event rate, in the PEARL trials published in the same issue. Adverse effects were similar in both groups in the EMERALD trials.

The study was appropriately powered to show safety and efficacy; however, a large proportion of patients prematurely discontinued the study, which may have skewed the results.  Additionally, the study’s exclusion criteria, which included hypertension or blood transfusions, weaken the study’s generalizability.

Click to read the study in NEJM

 

These [randomized controlled trials]: The EMERALD 1 and 2 trials, compared mean hemoglobin levels of hemodialysis patients who received either peginesatide or a traditional erythropoesis-stimulating agents (ESA) as treatment for anemia over an average of about 100 weeks.  The study found there was no significant difference in hemoglobin levels between patients receiving either treatment.  Additionally, the study found similar proportions of patients within each group that required blood transfusions, therapeutic phlebotomy, or experienced adverse events.  The study also found no significant difference in a prospectively determined composite safety end point, which included components such as death from any cause, stroke, myocardial infarction, heart failure, thromboemboloic events and other adverse events.  However, 8 patients in the peginesatide group developed neutralizing antibodies, while no ESA group patients developed epoetin-specific antibodies.

RELATED REPORTS

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis

Further reading:

1. Peginesatide as a potential erythropoiesis stimulating agent

2. PEARL trial results: peginesatide for anemia in chronic kidney disease patients not on dialysis

In sum: The EMERALD 1 and 2 trials evaluated the safety and efficacy of peginesatide for treatment of anemia in hemodialysis patients.

The study effectively demonstrated that peginesatide administered once a month was non-inferior to traditional erythropoiesis stimulating agents (ESAs) in maintaining hemoglobin at target levels.  This was found to be true for chronic kidney disease patients not on dialysis as well, albeit with a higher adverse event rate, in the PEARL trials published in the same issue (2). Adverse effects were similar in both groups in the EMERALD trials.

The study was appropriately powered to show safety and efficacy; however, a large proportion of patients prematurely discontinued the study, which may have skewed the results.  Additionally, the study’s exclusion criteria, which included hypertension or blood transfusions, weaken the study’s generalizability.

Click to read the study in NEJM

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

 

Tags: anemiaEPOhemodialysispeginesatide
Previous Post

High frequency oscillatory ventilation (HFOV) provides no mortality benefit over conventional ventilation in early respiratory distress

Next Post

Tendon transfer improves ankle function and reduces pain for chronic achilles tendinosis

RelatedReports

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia
StudyGraphics

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

May 4, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

April 22, 2022
#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis
StudyGraphics

#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis

April 14, 2022
Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis – the ASCEND-ID trial

April 8, 2022
Next Post

Tendon transfer improves ankle function and reduces pain for chronic achilles tendinosis

Emergency department visits account for large proportion of hospital encounters following discharge

Trigger exposure in migraine patients results in migraine with aura only in a small subset of patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.